In this study, we demonstrated that aberrantly activated APOBEC3B can induce TP53 G/C-to-A/T mutations in DLBCL, which may lead to proliferation and drug resistance and may contribute to R/R DLBCL. Here, TP53 is linked to diffuse large B-cell lymphoma.